Acquisitions (Tables)

12 Months Ended

Dec. 31, 2020

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the fair values of the assets acquired and liabilities assumed at the Acquisition Date (in thousands):


	January 10, 2020 (As Initially Reported)		Measurement Period and Other Adjustments		January 10, 2020 (As Adjusted)
Inventory	$	534	$	—	$	534
Prepaid assets	185		—		185
Property and equipment	16,839		—		16,839
Internally developed software	3,110		20		3,130
Customer relationships(1)	4,100		(270)		3,830
Long-term assets	346		—		346
Goodwill(2)	12,232		250		12,482
Total assets acquired	$	37,346	$	—	$	37,346
Long-term liabilities	(346)		—		(346)
Net assets acquired	$	37,000	$	—	$	37,000

(1) Acquired intangible assets consist of customer relationships which are amortized over seven years.

(2) The goodwill arising from the acquisition of HLI - Oncology is the amount the Company paid in excess of the fair value of the net assets acquired and was primarily for (i) the expected future cash flows derived from the existing business capabilities and infrastructure, (ii) expanding the Company's scientific expertise as a leading provider of Pharma Services and Next-Generation Sequencing and (iii) an enhanced Pharma Services menu including germline, whole exome and whole genome sequencing. All of the goodwill resulting from the acquisition of HLI - Oncology is expected to be deductible for income tax purposes.